EUVIMEDEUVIMED entdecken
Crossref

Cd44 Targeted Plga Nano-Medicine For Cancer Chemotherapy- A Comprehensive Review

Ravı KUMAR, Sunıta JHA, Akriti RAİ

Journal of Immunology and Clinical Microbiology · 2023

DOI: 10.58854/jicm.1315037 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Immunology and Clinical Microbiology, 2023. Verfasst von Ravı KUMAR und 2 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 84 Literaturangaben. Gefördert von: SD COLLEGE OF PHARMACY AND GLA UNIVERSITY.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In order to deliver therapeutic agents to tumour tissues more specifically, the scientific community has focused a lot of attention recently on unravelling the mystery of cluster of differentiation-44 (CD44). Additionally, drug delivery researchers are interested in using nanomedicines to target this receptor because of its over-expression in a variety of solid tumors. Conventional nanomedicines based on biodegradable polymers such as poly (lactide-co-glycolide) (PLGA) are often associated with insufficient cellular uptake by cancer cells, due to lack of active targeting moiety on their surface. Therefore, to address this limitation, CD44 targeted PLGA nanomedicines has gained considerable interest for enhancing the efficacy of chemotherapeutic agents. We have thoroughly covered the most recent developments in the design and synthesis of CD44-targeted PLGA nanomedicines in this review, which are being used to enhance tumor-targeted drug delivery. Additionally, we have talked about employing PLGA-based nanomedicines to co-target CD44 with additional targeting molecules such folic acid, human epidermal growth factor 2 (HER2), and monoclonal antibodies. Recent research on poly (lactic-co-glycolic acid) encapsulated platinum nanoparticles for the treatment of cancer was also covered in this review. We talk about the role that newly created nanomedicines can play in enhancing the efficacy and PK of existing therapy regimens. We offer insight into the development of more potent therapeutic regimens to enhance the clinical outcomes of cancer treatments by explaining the state-of-the-art of nanomedicine and analyzing their clinical benefits and problems.

Förderung

  • SD COLLEGE OF PHARMACY AND GLA UNIVERSITY

Zitieren

APA

KUMAR, R., JHA, S., & RAİ, A. (2023). Cd44 Targeted Plga Nano-Medicine For Cancer Chemotherapy- A Comprehensive Review. Journal of Immunology and Clinical Microbiology. https://doi.org/10.58854/jicm.1315037

Vancouver

KUMAR R, JHA S, RAİ A. Cd44 Targeted Plga Nano-Medicine For Cancer Chemotherapy- A Comprehensive Review. Journal of Immunology and Clinical Microbiology. 2023. doi:10.58854/jicm.1315037

BibTeX
@article{KUMAR2023,
  author = {KUMAR, Ravı and JHA, Sunıta and RAİ, Akriti},
  title = {Cd44 Targeted Plga Nano-Medicine For Cancer Chemotherapy- A Comprehensive Review},
  journal = {Journal of Immunology and Clinical Microbiology},
  year = {2023},
  doi = {10.58854/jicm.1315037}
}
Kostenlos starten →